Dr. Barlogie - ASH 2008 - Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5
Bart Barlogie, MD, PhD University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy Little Rock, Arkansas USA Member, IMF Board of Scientific Advisors
To view the video full screen, click on the small
button next to the volume control in the
lower right hand corner.